How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?

被引：54
作者：
Wong G. [1 ]
Sime F.B. [2 ,3 ]
Lipman J. [1 ,4 ]
Roberts J.A. [1 ,2 ,4 ]
机构：
[1] Burns Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, QLD
[2] School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA
[3] Therapeutics Research Centre, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Adelaide, SA
[4] Royal Brisbane and Women's Hospital, Level 3 Ned Hanlon Building, Butterfield St, Brisbane, 4029, QLD
来源：
BMC Infectious Diseases | / 14卷 / 1期
关键词：
Antibiotic; Pharmacodynamics; Pharmacokinetics; TDM;
D O I：
10.1186/1471-2334-14-288
中图分类号：
学科分类号：
摘要：
High mortality and morbidity rates associated with severe infections in the critically ill continue to be a significant issue for the healthcare system. In view of the diverse and unique pharmacokinetic profile of drugs in this patient population, there is increasing use of therapeutic drug monitoring (TDM) in attempt to optimize the exposure of antibiotics, improve clinical outcome and minimize the emergence of antibiotic resistance. Despite this, a beneficial clinical outcome for TDM of antibiotics has only been demonstrated for aminoglycosides in a general hospital patient population. Clinical outcome studies for other antibiotics remain elusive. Further, there is significant variability among institutions with respect to the practice of TDM including the selection of patients, sampling time for concentration monitoring, methodologies of antibiotic assay, selection of PK/PD targets as well as dose optimisation strategies. The aim of this paper is to review the available evidence relating to practices of antibiotic TDM, and describe how TDM can be applied to potentially improve outcomes from severe infections in the critically ill. © 2014 Wong et al.
引用
收藏
相关论文
共 134 条
  • [1] Bellomo R., Mortality in severe sepsis: an inconvenient truth, Crit Care Resusc, 12, 1, pp. 6-8, (2010)
  • [2] Boussekey N., Cantrel J., Dorchin Debrabant L., Langlois J., Devos P., Meybeck A., Chiche A., Georges H., Leroy O., Epidemiology, prognosis, and evolution of management of septic shock in a French intensive care unit: a five years survey, Crit Care Res Pract, 2010, (2010)
  • [3] Melamed A., Sorvillo F.J., The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data, Crit Care, 13, 1, (2009)
  • [4] Vincent J.-L., Rello J., Marchall J.C., Silva E., Anzueto A., Martin C.D., Moreno R., Lipman J., Gomersall C.D., Sakr Y., Reinhart K., International study of the prevalence and outcomes of infection in intensive care units, JAMA, 302, 21, pp. 2323-2329, (2009)
  • [5] Roberts J., Abdul Aziz M., Lipman J., Mouton J., Vinks A., Felton T., Hope W., Farkas A., Neely M., Schentag J., Drusano G., Frey O.R., Theuretzbacher U., Kuti J.L., Individualised antibiotic dosing for patients who are critically ill challenges and potential solutions, Lancet Inf Dis, 14, 6, pp. 498-509, (2014)
  • [6] Taccone F.S., Laterre P.-F., Dugernier T., Spapen H., Delattre I.K., Wittebole X., De Backer D., Layeux B., Wallemacq P., Vincent J.-L., Jacobs F., Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock, Crit Care, 14, 4, (2010)
  • [7] Roberts J.A., Paul S.K., Akova M., Bassetti M., De Waele J.J., Dimopoulos G., Kaukonen K.M., Koulenti D., Martin C., Montravers P., Rello J., Rhodes A., Starr T., Wallis S.C., Lipman J., DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients, Clin Infect Dis, 58, 8, pp. 1072-1083, (2014)
  • [8] Rea R.S., Capitano B., Bies R., Bigos K.L., Smith R., Lee H., Suboptimal aminoglycoside dosing in critically ill patients, Ther Drug Monit, 30, 6, pp. 674-681, (2008)
  • [9] Roberts J.A., Taccone F.S., Udy A.A., Vincent J.L., Jacobs F., Lipman J., Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens, Antimicrob Agents Chemother, 55, 6, pp. 2704-2709, (2011)
  • [10] van Zanten A.R., Polderman K.H., van Geijlswijk I.M., van der Meer G.Y., Schouten M.A., Girbes A.R., Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study, J Crit Care, 23, 3, pp. 422-430, (2008)
12345678910